Roger M. Lyons

10.6k total citations
137 papers, 4.6k citations indexed

About

Roger M. Lyons is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Roger M. Lyons has authored 137 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Hematology, 69 papers in Genetics and 27 papers in Molecular Biology. Recurrent topics in Roger M. Lyons's work include Acute Myeloid Leukemia Research (49 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (34 papers) and Platelet Disorders and Treatments (31 papers). Roger M. Lyons is often cited by papers focused on Acute Myeloid Leukemia Research (49 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (34 papers) and Platelet Disorders and Treatments (31 papers). Roger M. Lyons collaborates with scholars based in United States, France and Netherlands. Roger M. Lyons's co-authors include James B. Bussel, David J. Kuter, Janet L. Nichol, James N. George, N Stanford, Philip W. Majerus, Matthew Guo, Jeffrey S. Wasser, Vinod Pullarkat and Mikkael A. Sekeres and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Roger M. Lyons

133 papers receiving 4.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roger M. Lyons United States	34	2.9k	1.1k	1.0k	1.0k	747	137	4.6k
Joachim Kienast Germany	40	3.4k 1.2×	879 0.8×	1.2k 1.2×	1.5k 1.5×	1.8k 2.5×	98	7.3k
Ross Baker Australia	33	2.1k 0.7×	475 0.4×	2.9k 2.8×	2.3k 2.3×	458 0.6×	136	6.0k
Piérre Siè France	40	2.1k 0.7×	657 0.6×	1.7k 1.6×	1.8k 1.8×	755 1.0×	223	5.3k
Simon Panzer Austria	41	3.2k 1.1×	525 0.5×	1.0k 1.0×	1.8k 1.8×	449 0.6×	289	6.2k
Martin Hjorth Sweden	29	2.4k 0.8×	430 0.4×	763 0.7×	534 0.5×	1.3k 1.8×	46	3.5k
Sergio Siragusa Italy	26	960 0.3×	470 0.4×	748 0.7×	595 0.6×	360 0.5×	150	2.1k
Hanny Al‐Samkari United States	31	1.6k 0.5×	933 0.8×	527 0.5×	293 0.3×	275 0.4×	193	3.8k
Jean‐François Schved France	39	2.9k 1.0×	784 0.7×	933 0.9×	1.0k 1.0×	463 0.6×	209	4.7k
Bart J. Biemond Netherlands	30	2.4k 0.8×	1.4k 1.2×	250 0.2×	262 0.3×	982 1.3×	126	3.7k
Juan Carlos Souto Spain	31	1.9k 0.7×	439 0.4×	1.3k 1.3×	1.0k 1.0×	395 0.5×	145	3.7k

Countries citing papers authored by Roger M. Lyons

Since Specialization

Citations

This map shows the geographic impact of Roger M. Lyons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger M. Lyons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger M. Lyons more than expected).

Fields of papers citing papers by Roger M. Lyons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger M. Lyons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger M. Lyons. The network helps show where Roger M. Lyons may publish in the future.

Co-authorship network of co-authors of Roger M. Lyons

This figure shows the co-authorship network connecting the top 25 collaborators of Roger M. Lyons. A scholar is included among the top collaborators of Roger M. Lyons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger M. Lyons. Roger M. Lyons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Talpaz, Moshe, Aaron T. Gerds, Roger M. Lyons, et al.. (2025). A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis. Leukemia Research. 155. 107732–107732.

Maris, Michael B., Gilles Salles, Won Seog Kim, et al.. (2024). ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study. Targeted Oncology. 19(3). 321–332. 4 indexed citations

Gerds, Aaron T., et al.. (2022). Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study. Clinical Lymphoma Myeloma & Leukemia. 22(7). e532–e540. 3 indexed citations

Manda, Sudhir, Habte Yimer, Stephen J. Noga, et al.. (2020). Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. Clinical Lymphoma Myeloma & Leukemia. 20(11). e910–e925. 11 indexed citations

Cuker, Adam, Jenny M. Despotovic, Rachael F. Grace, et al.. (2020). Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method. Research and Practice in Thrombosis and Haemostasis. 5(1). 69–80. 15 indexed citations

Witzig, Thomas E., Kami J. Maddocks, Sven de Vos, et al.. (2019). Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 37(15_suppl). 7519–7519. 12 indexed citations

Lyons, Roger M., Carole Paley, Jason Esposito, et al.. (2017). Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years. Leukemia Research. 56. 88–95. 39 indexed citations

Cines, Douglas B., Terry Gernsheimer, Jeffrey S. Wasser, et al.. (2015). Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. International Journal of Hematology. 102(3). 259–270. 67 indexed citations

Kuter, David J., James B. Bussel, Adrian C. Newland, et al.. (2013). Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. British Journal of Haematology. 161(3). 411–423. 203 indexed citations

10.

Raskob, Gary E., Harry R. Büller, Pantep Angchaisuksiri, et al.. (2013). Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients. Blood. 122(21). 211–211. 18 indexed citations

11.

Wang, Eunice S., Roger M. Lyons, Richard A. Larson, et al.. (2012). A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology & Oncology. 5(1). 71–71. 48 indexed citations

12.

Lyons, Roger M., et al.. (2011). Oral ezatiostat HCl (Telintra®, TLK199) and Idiopathic Chronic Neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor. Journal of Hematology & Oncology. 4(1). 43–43. 18 indexed citations

13.

Stone, Richard M., Mikkael A. Sekeres, Guillermo Garcia‐Manero, & Roger M. Lyons. (2008). Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.. PubMed. 6(12). 1–15. 8 indexed citations

14.

Gabrilove, Janice, Ronald Paquette, Roger M. Lyons, et al.. (2008). Phase 2, single‐arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. British Journal of Haematology. 142(3). 379–393. 62 indexed citations

15.

Deitcher, Steven R., Craig M. Kessler, Geno J. Merli, et al.. (2006). Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period. Clinical and Applied Thrombosis/Hemostasis. 12(4). 389–396. 294 indexed citations

16.

Bussel, James B., David J. Kuter, James N. George, et al.. (2006). AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP. New England Journal of Medicine. 355(16). 1672–1681. 386 indexed citations

17.

Lyons, Roger M., et al.. (2005). Microdialysis sampling and the clinical determination of topical dermal bioequivalence. International Journal of Pharmaceutics. 308(1-2). 1–7. 16 indexed citations

18.

George, James N., Gary E. Raskob, Sara K. Vesely, et al.. (2003). Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti‐D with routine care. American Journal of Hematology. 74(3). 161–169. 49 indexed citations

19.

Bussey, Henry I. & Roger M. Lyons. (1998). Controversies in Antithrombotic Therapy for Patients with Mechanical Heart Valves. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 18(3). 451–455. 2 indexed citations

20.

Spiro, Theodore E., et al.. (1994). Efficacy and Safety of Enoxaparin to Prevent Deep Venous Thrombosis after Hip Replacement Surgery. Annals of Internal Medicine. 121(2). 81–89. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact